Plain-English translation of NCT05817851 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether high-dose intravenous vitamin C can help patients who go into shock after surviving a cardiac arrest. After a cardiac arrest, many patients develop a dangerous condition called post-cardiac arrest shock, where the heart and blood vessels fail, leading to organ damage. Researchers believe that vitamin C may reduce inflammation and injury in this critical period.
After cardiac arrest, up to one-third of patients die from the shock and organ failure that follows in the first hours. Laboratory studies suggest this medication may protect organs and improve blood vessel function during this dangerous time, but this needs to be tested in real patients.
You likely qualify if…
You likely don't qualify if…
If you are in the treatment group, you will receive high-dose vitamin C (and a B vitamin called thiamine) through an IV every 6 hours for 3 days, starting within one hour of being enrolled. Both groups will receive standard intensive care for post-cardiac arrest shock. You will be monitored in the ICU, and the study team will track your recovery for 28 days after enrollment.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
France